LXEO
Lexeo Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website lexeotx.com
- Employees(FY) -
- ISIN US52886X1072
Performance
-4.48%
1W
+13.25%
1M
-10.88%
3M
+24.89%
6M
+3.2%
YTD
+37.81%
1Y
Profile
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Technical Analysis of LXEO 2024-05-10
Overview:
In analyzing the technical indicators for LXEO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential in...
Recent News & Updates
- 2024-05-14 00:00
- 2024-05-13 21:55
- 2024-05-08 19:00
- 2024-05-06 19:30
- 2024-04-21 19:30
- 2024-04-15 19:30
- 2024-03-13 04:22
- 2024-03-10 19:42
- 2024-03-10 19:30
- 2024-02-05 07:00
- 2024-02-04 18:00
- 2024-01-03 07:00
- 2024-01-02 18:00
- 2023-12-18 07:00
- 2023-12-17 18:00
- 2023-12-13 04:59
- 2023-12-11 07:00
- 2023-12-10 23:05
- 2023-12-10 18:00
- 2023-11-30 08:42
- 2023-11-02 09:51
Page 1 of 1
previousnext